Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert CommitteeAccesswire • 03/02/23
Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health RegisterAccesswire • 02/15/23
Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 12/14/22
Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022Accesswire • 12/02/22
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology PatentAccesswire • 12/01/22
Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive AgreementAccesswire • 10/27/22
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology ConfereAccesswire • 10/26/22
Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24Accesswire • 10/17/22
Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology PatentAccesswire • 08/01/22
1.2M Shares of Nutriband Inc. to be Cancelled from Total Outstanding Shares Following Final Court Judgment in Favor of the CompanyAccesswire • 07/26/22
Nutriband Inc. Registers New Company Branch in Ecuador with Plans to Expand into the South American MarketAccesswire • 07/22/22
Nutriband Inc. Successfully Obtains Court Verdict for Recovery of Shares Constituting 15% of Its Total Outstanding SharesAccesswire • 07/15/22
